SCHEDULE: Baselake Partners Discloses 7.3% Stake in Passage Bio

Baselake Partners, LP, Baselake Management, LLC, and David Paolella have filed a Schedule 13G reporting a 7.3% beneficial ownership stake in Passage Bio, Inc.

Summary

• Baselake Partners, LP, along with its investment manager Baselake Management, LLC and managing member David Paolella, reported beneficial ownership of 235,058 shares of Passage Bio, Inc. common stock.
• The reported stake represents 7.3% of the issuer's total outstanding common stock, based on 3,207,810 shares outstanding as of May 7, 2026.
• The reporting persons share voting and dispositive power over the entire 235,058 share position.
• The filing confirms the acquisition was made for investment purposes and not to influence or change control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure of institutional ownership that does not imply a change in company strategy or financial performance.

Positives

• Institutional investor confidence indicated by a significant 7.3% equity position.
• Clear disclosure of beneficial ownership structure and shared voting/dispositive power.

Negatives

• None identified in this regulatory disclosure.

Risks

• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
• The investment is subject to market volatility inherent in the biotechnology sector.

Future Outlook

The filing states the securities were not acquired for the purpose of changing or influencing the control of the issuer, indicating a passive investment stance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by investment firms in the biotechnology sector often signal long-term conviction in a company's clinical pipeline or valuation, though they remain passive in nature.

Comparison to Industry Standards

• The 7.3% stake is a standard threshold for institutional investors in small-cap biotech firms.
• The filing follows standard SEC regulatory requirements for passive investors exceeding the 5% ownership threshold.

Stakeholder Impact

• Shareholders may view the entry of an institutional investor as a sign of market validation for the company's prospects.

Next Steps

• The reporting persons may file amendments if there are material changes in their percentage of ownership.

Key Dates

Keywords

Passage Bio, Baselake Partners, Schedule 13G, Biotechnology, Institutional Ownership, Common Stock